AU Patent

AU2012203520A1 — Salts of N-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Assigned to Novartis AG · Expires 2012-07-05 · 14y expired

What this patent protects

C:\NRPorbtDCC\RBRW401280.1 DOC-6/15/2012 Salts of N-(6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4' (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide are prepared and characterized.

USPTO Abstract

C:\NRPorbtDCC\RBRW401280.1 DOC-6/15/2012 Salts of N-(6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4' (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide are prepared and characterized.

Drugs covered by this patent

sonidegib-phosphate (SONIDEGIB PHOSPHATE)

Patent Metadata

Patent number: AU2012203520A1
Jurisdiction: AU
Classification: —
Expires: 2012-07-05
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.